News
OPORF
0.350
NaN%
--
hVIVO Sets Date for Interim Results and Schedules Analyst and Investor Events
TipRanks · 6d ago
hVIVO expands into dermatology and women’s health with acquisition of CRS Berlin
TipRanks · 08/27 06:07
hVIVO Orderbook Doubles as Second-Half-Weighted Revenue Drives Growth Outlook
TipRanks · 07/23 06:11
hVIVO appoints Grant Thornton as new auditor after tender
TipRanks · 07/13 06:10
hVIVO wins Decoy Therapeutics consultancy mandate for next-generation respiratory antivirals
TipRanks · 06/01 11:09
hVIVO grants performance-linked share options to senior leadership under 2024 LTIP
TipRanks · 05/29 06:19
hVIVO Showcases Integrated Early-Stage Drug Development Platform at Capital Markets Day
TipRanks · 05/20 06:13
hVIVO Shareholders Back All Resolutions at Annual General Meeting
TipRanks · 05/13 12:41
Stifel Nicolaus Remains a Hold on Open Orphan Plc (HVO)
TipRanks · 05/07 17:05
hVIVO wins £6m influenza human challenge trial to test monoclonal antibody
TipRanks · 05/07 06:24
hVIVO Director Brendan Buckley Sells Shares Ahead of Board Exit
TipRanks · 04/24 17:17
Shore Capital Sticks to Their Buy Rating for Open Orphan Plc (HVO)
TipRanks · 04/23 03:15
hVIVO Wins Landmark Phase III Human Challenge Contract for ILiAD’s Whooping Cough Vaccine
TipRanks · 04/22 06:26
hVIVO Publishes 2025 Annual Report and Sets May AGM Date
TipRanks · 04/17 06:10
Open Orphan Plc Earnings Call: Diversifying Amid Strain
TipRanks · 04/17 00:04
Stifel Nicolaus Keeps Their Hold Rating on Open Orphan Plc (HVO)
TipRanks · 04/15 21:05
hVIVO Reshapes Clinical Platform as 2025 Profits Slide on Sector Headwinds
TipRanks · 04/15 06:14
hVIVO Rebrands as Unified End-to-End Clinical Development Partner
TipRanks · 04/14 06:48
hVIVO seals Traws Pharma deal for Phase 2a influenza human challenge trial
TipRanks · 04/14 06:15
hVIVO sets 15 April date to unveil 2025 final results
TipRanks · 04/07 06:07
More
Webull provides a variety of real-time OPORF stock news. You can receive the latest news about Hvivo through multiple platforms. This information may help you make smarter investment decisions.
About OPORF
hVIVO plc is a United Kingdom-based purpose-built, full-service international clinical development partner and engaged in human challenge trials serving biopharma companies. The Company has an end-to-end platform designed to bring important medicines to patients faster: spanning preclinical strategy, first in human studies, Phase II patient trials and specialist laboratory services, delivered through a participant database, wholly owned sites and laboratories across the UK and Germany. The Company offers integrated service lines which include consulting, clinical trials, human challenge trials, and laboratories. Its consulting provides preclinical and clinical strategy, encompassing non-clinical, clinical, CMC, pharmacokinetics, data management, biostatistics, and regulatory support to guide trial design, execution, and interpretation. The Company is also focused on Phase I/II clinical studies, particularly in dermatology and women's health.